WHO ICTRP trial
The effectiveness of spironolactone in group 1 pulmonary hypertension patients
IRCT20171120037376N1 · Iranian Registry of Clinical Trials (IRCT) · Recruiting
Key facts
| Trial ID | IRCT20171120037376N1 |
|---|---|
| Public title | The effectiveness of spironolactone in group 1 pulmonary hypertension patients |
| Scientific title | A clinical trial to compare the effectiveness of spironolactone with the standard treatment in right ventricular function in group 1 pulmonary hypertension patients |
| Primary sponsor | Vice Chancellor for Research, Mashhad University of Medical Sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Recruiting |
| Study type | interventional |
| Phase | 2 |
| Countries | Iran (Islamic Republic of) |
| Conditions | Group 1 pulmonary hypertension. Other specified pulmonary heart diseases;Other specified pulmonary heart diseases |
| Interventions | Intervention 1: Control group: Who will receive 10-20 mg of tadalafil and 125 mg of bosentan once or twice a day for four months. Intervention 2: Intervention group: Who will receive 10-20 mg of tadalafil and 125 mg of bosentan once or… |
| Registration date | Nov 20, 2017 |
| Target size | 50 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: